BioCentury
ARTICLE | Clinical News

BMS-955176: Additional Phase IIa data

August 3, 2015 7:00 AM UTC

Data from 28 patients with HIV-1 subtype B in the open-label Part B portion of the international Phase IIa AI468002 trial showed that once-daily 40 mg oral BMS-955176 plus 400 mg Reyataz atazanavir r...